|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0014822,
umls-concept:C0023981,
umls-concept:C0026336,
umls-concept:C0035647,
umls-concept:C0199176,
umls-concept:C0205225,
umls-concept:C0238644,
umls-concept:C0282440,
umls-concept:C1096777,
umls-concept:C1257890,
umls-concept:C1516213,
umls-concept:C1707391,
umls-concept:C2003941,
umls-concept:C2603343
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-5-25
|
|
pubmed:abstractText |
Epoetin (EPO) administration reduces the need for transfusion. Identifying patients at high risk of anemia requiring red blood cell (RBC) transfusion is needed. This multicentric phase III trial tested epoetin alpha (EPOalpha) administration according to our risk model on the basis of three clinical parameters: hemoglobin (Hb) <12 g/dl, lymphocytes <or=700/microl, and/or performance status (PS) >1.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:AgostiniCC,
pubmed-author:AnglaresAA,
pubmed-author:BachelotTT,
pubmed-author:BironPP,
pubmed-author:BlayJ-YJY,
pubmed-author:DebourdeauPP,
pubmed-author:DesseigneFF,
pubmed-author:DussartSS,
pubmed-author:GhesquieresHH,
pubmed-author:GoillotCC,
pubmed-author:GuastallaJ-PJP,
pubmed-author:LancryLL,
pubmed-author:Le CesneAA,
pubmed-author:MayeurDD,
pubmed-author:Ray-CoquardII
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1105-12
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19174452-Adult,
pubmed-meshheading:19174452-Aged,
pubmed-meshheading:19174452-Aged, 80 and over,
pubmed-meshheading:19174452-Anemia,
pubmed-meshheading:19174452-Chemoprevention,
pubmed-meshheading:19174452-Erythropoietin,
pubmed-meshheading:19174452-Female,
pubmed-meshheading:19174452-Hematinics,
pubmed-meshheading:19174452-Humans,
pubmed-meshheading:19174452-Male,
pubmed-meshheading:19174452-Middle Aged,
pubmed-meshheading:19174452-Models, Biological,
pubmed-meshheading:19174452-Neoplasms,
pubmed-meshheading:19174452-Prospective Studies,
pubmed-meshheading:19174452-Recombinant Proteins,
pubmed-meshheading:19174452-Risk Factors
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group.
|
|
pubmed:affiliation |
Department of Medical Oncology, Léon Bérard Comprehensive Cancer Center, University of Lyon, and EA 4128 SIS Individu Santé, Société, Lyon, France. ray@lyon.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
